Possible Trump FDA Commish Candidate Favors (Much) Lighter Touch

Jim O'Neill, a Silicon Valley investment manager, would be an unusual choice to head FDA, not just because he isn’t a physician, but because he’s favored substantially reducing FDA's role in assessing product effectiveness. While some experts are highly skeptical about O'Neill, who worked at HHS in the Bush administration, others suggest he could champion much-needed change at the agency.

Capitol House

A purported candidate to run FDA under the Trump administration would bring what some consider troubling views and experience to the commissioner post, but regulatory affairs stakeholders say Silicon Valley investor Jim O'Neill could be an interesting pick.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation

US FDA Layoffs Expected To Have Ripple Effect On Cosmetics Office Functions

 
• By 

Functions supporting the US Food and Drug Administration’s Office of Cosmetics and Colors have been impacted by the reduction-in-force.

European Commission’s Omnibus VII Bans Two Nail Care Ingredients Starting In September

 

Two nail care ingredients included in the European Commission’s Omnibus VII, which includes about two dozen ingredients overall, are banned in Europe in September.

Cosmetics Europe Argues Against Potential Ban Of Common Fragrance, Cosmetic Ingredient Ethanol

 

Cosmetics Europe is working to obtain derogations for three fragrance and/or cosmetic substances that may be categorized as carcinogenic, mutagenic or reprotoxic, which could result in a ban of their use under the Cosmetic Products Regulation.